FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the pharmaceutical industry and namely to the use of an extract of the basidial fungus Inonotus obliquus to inhibit the replication of SARS-CoV-2. The extract of the basidial fungus Inonotus obliquus, which was being obtained by water extraction at a temperature of 50-95 °C for a period of 1.0 to 72 hours to be used to inhibit the replication of SARS-CoV-2, demonstrates 50% antiviral dose-dependent activity against SARS-CoV-2 during Vero E6 and Vero cell culture tests at a concentration ranging from 0.75 to 11.6 mcg/ml.
EFFECT: described above extract is effective for inhibiting the replication of SARS-CoV-2.
1 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SARS-COV-2 CORONAVIRUS REPLICATION INHIBITOR BASED ON MELANIN FROM INONOTUS OBLIQUUS FUNGUS | 2020 |
|
RU2747018C1 |
| SARS-CoV-2 CORONAVIRUS REPLICATION INHIBITOR BASED ON HUMIC SUBSTANCES | 2020 |
|
RU2752872C1 |
| METHOD FOR OBTAINING AN AQUEOUS EXTRACT OF FIREWEED LEAVES EPILOBIUM ANGUSTIFOLIUM L., WHICH EXHIBITS INHIBITORY ACTIVITY AGAINST SARS-CoV-2 CORONAVIRUS AND HERPES SIMPLEX VIRUS TYPE 2 IN VITRO | 2022 |
|
RU2788172C1 |
| USE OF ALCOHOLIC EXTRACT OF AERIAL PARTS OF MARAL ROOT RHAPONTICUM CARTHAMOIDES AS AGENT, INHIBITING ACTIVITY OF CORONAVIRUS SARS-CoV-2 AND HERPES SIMPLEX VIRUS TYPE 2 IN VITRO AND METHOD FOR PRODUCTION THEREOF | 2023 |
|
RU2825393C1 |
| AN ANTIVIRAL AGENT AGAINST SARS-COV-2 CORONAVIRUS | 2022 |
|
RU2788762C1 |
| WOUND HEALING OINTMENT FOR EXTERNAL USE | 2022 |
|
RU2787233C1 |
| INHIBITOR OF REPRODUCTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 | 2008 |
|
RU2375073C1 |
| MELANINE ANTIVIRAL AGENT | 2011 |
|
RU2480227C2 |
| NUTRIENT MEDIUM FOR CULTIVATING BASIDIOMYCETE FUNGUS INONOTUS OBLIQUUS | 2021 |
|
RU2808749C2 |
| STRAIN OF BASIDIOMYCETE INONOTUS OBLIQUUS - PRODUCER OF MELANIN PIGMENT POSSESSING ANTIVIRAL AND ANTITUMORAL ACTIVITY | 2019 |
|
RU2716590C1 |
